The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.
Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by chance), double-blind (neither the patient or the study doctor will know the name of the assigned treatment), multicenter study to determine the efficacy, safety, and tolerability of canagliflozin 300 mg compared to sitagliptin 100 mg (an antihyperglycemic drug) in patients with T2DM who are not achieving an adequate response from current antihyperglycemic therapy with metformin and sulphonylurea to control their diabetes. Approximately 720 patients with T2DM who are receiving combination therapy with metformin and sulphonylurea will receive the addition of once-daily treatment with canagliflozin 300 mg or sitagliptin 100 mg capsules for 52 weeks. Patients will participate in the study for approximately 59 to 72 weeks. During treatment, patients will be monitored for safety by review of adverse events, results from laboratory tests, 12-lead electrocardiograms (ECGs), vital signs measurements, body weight, physical examinations, and self monitored blood glucose (SMBG) measurements. The primary outcome measure in the study is the effect of canagliflozin compared to sitagliptin on hemoglobin A1c (HbA1c) after 52 weeks of treatment. Study drug will be taken orally (by mouth) once daily before the first meal each day unless otherwise specified. Patients will take single-blind placebo for 2 weeks before randomization. After randomization, patients in the study will take double-blind canagliflozin 300 mg or matching sitagliptin 100 mg for 52 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
756
One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Change in HbA1c From Baseline to Week 52
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Time frame: Day 1 (Baseline) and Week 52
Percentage of Patients With HbA1c <7% at Week 52
The table below shows the percentage of patients with HbA1c \<7% at Week 52 in each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the percentage.
Time frame: Week 52
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Time frame: Day 1 (Baseline) and Week 52
Percent Change in Body Weight From Baseline to Week 52
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean percent change.
Time frame: Day 1 (Baseline) and Week 52
Change in Systolic Blood Pressure (SBP) From Baseline to Week 52
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Time frame: Day 1 (Baseline) and Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Goodyear, Arizona, United States
Unnamed facility
Mesa, Arizona, United States
Unnamed facility
Escondido, California, United States
Unnamed facility
Fresno, California, United States
Unnamed facility
Greenbrae, California, United States
Unnamed facility
La Mesa, California, United States
Unnamed facility
Laguna Hills, California, United States
Unnamed facility
Lancaster, California, United States
Unnamed facility
Long Beach, California, United States
...and 174 more locations
Percent Change in Triglycerides From Baseline to Week 52
The table below shows the mean percent change in triglycerides from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Time frame: Day 1 (Baseline) and Week 52
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52
The table below shows the mean percent change in HDL-C from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
Time frame: Day 1 (Baseline) and Week 52